Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
about
Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLCAltering the response to radiation: sensitizers and protectorsA high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancerRadiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Personalized radiotherapy: concepts, biomarkers and trial designRadiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinomaNCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapyImproving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.Lessons learned from radiation oncology clinical trials.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.The potential of PARP inhibitors in neuro-oncology.Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrenceEffect of cancer-associated fibroblasts on radiosensitivity of cancer cells.UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization.An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology.Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkersIGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Enhancing the efficacy of radiation therapy: premises, promises, and practicality.The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?Enhanced Radiotherapy using Bismuth Sulfide Nanoagents Combined with Photo-thermal Treatment.Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.Single cell whole genome sequencing reveals that NFKB1 mutation affects radiotherapy sensitivity in cervical cancer.Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
P2860
Q26852202-10394E0C-BD35-4957-BD44-A889CA9EBECBQ26865377-4434A0CB-D419-428F-B9D5-AA2BAF5DF13EQ33946208-6ED12688-B1A7-486C-A29D-76C8C8EF899DQ35966191-A783F62D-36AB-440A-BC0D-C9C15C989C59Q36235704-39F0801E-4D8D-451C-95EB-83A224C64B05Q36368072-5373E3AA-371B-4460-9928-DB9834006B10Q36507559-2F623A72-5A09-4823-9060-AE1AFE1B7ADBQ37001172-4768A51F-645E-4DC4-A4D6-9B21DA2212DBQ37059799-CEC4D95C-5F32-42AB-A6C7-89A44CAABFA2Q37092020-251D3AB9-7047-404B-8C32-77CA1067E1A2Q37403232-17C34F02-4037-473F-AEC8-6D50BDC606FAQ37615630-59264604-C4E6-4AE8-BB9A-7DA61B663DC1Q37662359-A55C8B88-187E-4A12-9EBE-C1D3A801774FQ38028791-527B9259-1590-4312-BD87-0B35E7633D34Q38233068-3667533E-0615-417C-9430-9FAFE655D200Q38263008-1C1F50A5-B443-403A-9A33-3AE19553D4DAQ38536374-A9AEF35B-A35B-49BA-90D0-42ECF84F1060Q38661469-F4521624-6E80-4DDC-9BFF-B5594B1623C6Q38696038-B2D38C1F-5913-4B6D-BE49-5F603415823BQ38755412-F20C567C-51D2-449E-8574-E7C5DAB3C939Q38911199-0974B421-421D-4DE9-ACA4-9BC909162FC7Q38927010-0C77ED09-46D9-4DDA-B67D-D36B1DC31CE8Q39163331-3CF69E20-8139-46BC-9AB7-61398F77571FQ39668588-8F4C3115-799C-4D7A-8694-F09F493B6264Q42545565-0F7EE8C2-1165-4D3C-A5AE-9E1FD320B7C4Q42547560-9B392AC0-806D-49EF-B0DF-C56F3EF16892Q47329255-BC3AA46F-4122-4BA7-A7B2-6CD008D97540Q47880159-A6A9AB40-F43E-496C-83EC-63EF17C7EAA2Q54950563-3A931C37-7F37-490B-9F68-CA623E55B385Q55040614-5D99FBB0-842C-463B-ACA3-F87493CB3E65Q59133970-1D1638C8-EBFC-425A-8522-5C2F6246540E
P2860
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
@en
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
@nl
type
label
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
@en
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
@nl
prefLabel
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
@en
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
@nl
P2093
P2860
P50
P921
P356
P1476
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
@en
P2093
C M Nutting
J Macdougall
K J Harrington
N G Burnet
T B Brunner
T S Maughan
P2860
P2888
P304
P356
10.1038/BJC.2011.240
P407
P577
2011-07-19T00:00:00Z